SCHEMBL4828906

SCHEMBL4828906

CC(C)(C)OC(=O)N1CCN(Cc2ccccc2)[C@H](C(N)=O)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.48
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46
STS P08842 1/20 0.46
SPHK1 Q9NYA1 1/20 0.45
BRD4 O60885 1/20 0.44
BCHE P06276 1/20 0.44
HTR6 P50406 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
USP30 Q70CQ3 2/20 0.43
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
ACHE P22303 1/20 0.43
SCD O00767 1/20 0.42
SCD5 Q86SK9 1/20 0.42
GAA P10253 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828897 1.00 GPR119 (0.48) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL31740665 0.90 GPR119 (0.50) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL8568595 0.90 GPR119 (0.50) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL27006693 0.89 GPR119 (0.49) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL29060414 0.87 GPR119 (0.53) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL30867751 0.87 GPR119 (0.50) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL17913813 0.87 GPR119 (0.50) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL12340707 0.85 GPR119 (0.50) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL15055262 0.85 GPR119 (0.50) GPR119JAK2JAK1OPRD1OPRK1
SCHEMBL14198702 0.85 GPR119 (0.50) GPR119JAK2JAK1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365077-B2 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor SMITHKLINE BEECHAM P.L.C. (GB) 2008-04-29 US disclosed
US-20060252769-A1 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor SMTIHKLINE BEECHAM P.L.C. (GB) 2006-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252769-A1 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor HCRTR2, HCRTR1, NPSR1 GPR119 60/4885JAK2 1868/4885JAK1 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.